CurrentUnitedHealthcarePolicy CS305IN.09

Chemotherapy Observation or Inpatient Hospitalization (for Indiana Only)

UnitedHealthcare Indiana-specific medical policy defining when chemotherapy administration requires facility observation or inpatient hospitalization for adults (>=18 years), listing drug regimens and clinical conditions that necessitate inpatient monitoring or may require observation/inpatient care; includes provider expectations and references to InterQual LOC and Indiana IHCP inpatient guidance.

Policy Summary

PayerUnitedHealthcare

PolicyChemotherapy Observation or Inpatient Hospitalization (for Indiana Only)

Policy CodePolicy CS305IN.09

Change TypeRevisedUpdated references

Effective DateJun 1, 2026

Next Review Date

Key ActionDo not apply this policy to individuals under 18 years of age; follow written protocol and use InterQual LOC or Indiana IHCP guidance for unspecified cases.

SourceLink

POLICY UPDATE CHANGES

Revised drug regimen requirements for an inpatient stay and removed list of applicable cancer types for the listed regimens.

Updated Clinical Evidence and References sections to reflect the most current information.

Supporting Information updated; previous policy CS305IN.08 archived.

7Example regimens listed as requiring inpatient stay

3Clinical conditions listed that may require observation

1State-specific policy (Indiana)

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Summary

Scope: UnitedHealthcare Indiana-specific medical policy CS305IN.09 (effective June 1, 2026) addressing when chemotherapy/antineoplastic therapy administration for adults (aged ≥18 years) requires facility observation or an inpatient hospital stay. Coverage stance: mixed — most chemotherapy can be given in the office, clinic, or home, but specific regimens, monitoring needs, or complications require observation or inpatient admission. Headline: Adults in Indiana receiving complex or multi-day regimens or those with certain toxicity risks or complications may require observation or inpatient hospitalization per this policy and referenced InterQual and Indiana IHCP guidance.

Key thresholds and quick facts

Methotrexate level thresholds for leucovorin escalation> 20 µmol/L at 0 hour; > 1.0 µmol/L at 24 hours; > 0.1 µmol/L at 48 hours; continue until levels < 0.1 µmol/L

High-dose methotrexate dosing> 500 mg/m2

Ifosfamide high-dose definition> 1 g/m2/day

Coordination duration indicating complexityMultiple infusions or multiple drugs over 96 hours

Example regimens listed requiring inpatient stay (count)7 regimens listed as examples

Clinical conditions that may require observation (count)3 conditions listed

State-specific policy flagApplies to Indiana only

Medical Necessity Criteria

Clinical conditions that may require observation stay

The following clinical conditions or complications of cancer chemotherapy may require an observation stay:

ANY of the following

Congestive heart failure or chronic renal failure requiring high volume fluid infusions
Known hypersensitivity reactions from previous infusion
TACE or intra-arterial chemotherapy: TACE (Transcatheter Arterial Chemoembolization) or intra-arterial chemotherapy infusion

Other clinical conditions

Conditions requiring observation or inpatient hospital treatment other than those noted will be reviewed:

Provider Actions & Requirements

Documentation Required

Age restriction

Policy applies only to adults; do not apply to individuals under 18 years of age.

Documentation Required

Written protocol requirement

A written protocol will be expected to be followed by the provider administering the chemotherapy drug.

Prior Authorization

Extension of inpatient stay

Any requests for an extension of the inpatient stay beyond the recommended day(s) must be clinically reviewed.

Coding

No specific CPT/HCPCS/ICD-10 codes listedmixed

No codes listed

Background, Evidence & Definitions

This policy delineates settings where chemotherapy can be administered—home, physician’s office, outpatient clinic, facility observation unit, or inpatient hospital—and recognizes that most antineoplastic therapy is safely given outside the hospital but that some regimens or patient-specific risks necessitate facility observation or inpatient care. The policy references the InterQual Level of Care (LOC) criteria for Acute Adult Hematology/Oncology (Complications or Disease Progression and Treatments) and directs providers to the Indiana Health Coverage Programs (IHCP) Provider Reference Module for Inpatient Hospital Services when inpatient admission is required. Rationale for inpatient monitoring includes the need for complex coordination of multiple infusions or drugs over extended periods (e.g., ~96 hours), continuous cardiac or intensive physiologic monitoring, frequent laboratory or therapeutic drug-level assessments (for example methotrexate level monitoring), aggressive fluid management, alkalinization and electrolyte replacement, vasopressor support, proximity to intensive care, or other toxicity-management interventions that cannot be safely provided in outpatient settings.

Evidence / Source	Key point
Systematic review on therapeutic drug monitoring for methotrexate (Chellal et al., 2025)
Supports vigilant methotrexate monitoring to reduce toxicity and optimize outcomes in high-dose methotrexate therapy
Retrospective/outpatient feasibility studies (Tirtei 2024)
Findings indicate manageable toxicity of prolonged high-dose ifosfamide allowing outpatient administration with scheduled monitoring
Retrospective/outpatient feasibility studies (Nelles 2023)
DA-EPOCH-R can be delivered primarily in an outpatient setting with inpatient admission as needed for complications such as febrile neutropenia
Retrospective/outpatient feasibility studies (Banh 2021)
Outpatient ifosfamide administration was feasible and associated with fewer hospital days though inpatient patients had higher severe adverse event rates
Retrospective/outpatient feasibility studies (Li 2020)
Routine outpatient administration of DA-EPOCH was reported as safe and feasible with no hospitalizations during outpatient infusions in the study cohort
Prospective cohort study (Chen 2020)
Quality of life and adverse events were similar between inpatient and outpatient chemotherapy for esophageal SCC, supporting outpatient feasibility in selected patients
Retrospective cohort study (Rodrigues 2020)
Outpatient high-dose cytarabine appeared safe and effective in the reported cohort, though older patients had increased toxicity
Case series (Keshvani 2019)
Transitioning EPOCH-based regimens to ambulatory infusion improved patient-reported quality of life and was feasible with appropriate monitoring
Guideline (ASCO-ONS Antineoplastic Therapy Administration Safety Standards, 2024)
Provides updated standards and best practices for safe administration and monitoring of antineoplastic therapies across settings including home and outpatient

TACE (Transcatheter Arterial Chemoembolization): procedure in which the blood supply to a tumor is blocked after anticancer drugs are given in blood vessels near the tumor (National Cancer Institute, 2022).

Revision History

06/01/2026material_changeLatest

Revised drug regimen requirements for an inpatient stay; removed list of applicable cancer type(s) for the listed regimens; Supporting Information updated and previous policy version CS305IN.08 archived.

06/01/2026non_material_update

Updated Clinical Evidence and References sections to include clinical evidence citations through 2025 and referenced ASCO-ONS Antineoplastic Therapy Administration Safety Standards (2024).